Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC

May 31, 2026 By The ASCO Post Staff

Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).

Related Content